Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

SELLAS Life Sciences Group, Inc. Common Stock (SLS)

Pharmaceutical Preparations

https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

7 TIMES SQUARE, SUITE 2503
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/12/2008

Market Cap

84,918,899

Shares Outstanding

42,260,000

Weighted SO

43,487,072

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

NLSP --.--%

MREO --.--%

ARAV --.--%

DAWN --.--%

RVPHW --.--%

EYEN --.--%

CGTX --.--%

RNAZ --.--%

KOD --.--%

Beta

2.4090

Last Div

0.0000

Range

0.5-1.9

Chg

0.0500

Avg Vol

947950

Mkt Cap

84918899

Exch

NASDAQ

Country

US

Phone

646 200 5278

DCF Diff

1.2579

DCF

0.0621

Div Yield

0.0000

P/S

0.0000

EV Multiple

-3.0125

P/FV

26.1148

Div Yield %

0.0000

P/E

-2.2089

PEG

-0.0610

Payout

0.0000

Current Ratio

1.0213

Quick Ratio

1.0213

Cash Ratio

0.7677

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

0.7893

ROA

-2.2779

ROE

-173.4962

ROCE

-8.2463

NI/EBT

1.0000

EBT/EBIT

1.3586

EBIT/Rev

0.0000

Debt Ratio

0.0458

D/E

0.2376

LT Debt/Cap

0.0524

Total Debt/Cap

0.1920

Int Coverage

0.0000

CF/Debt

-46.4740

Equity Multi

5.1902

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-0.5580

FCF/Share

-0.7055

Cash/Share

0.1605

OCF/Sales

0.0000

FCF/OCF

1.2643

CF Coverage

-46.4740

ST Coverage

-60.5650

CapEx Coverage

-3.7835

Div&CapEx Cov

-3.7835

P/BV

26.1148

P/B

26.1148

P/S

0.0000

P/E

-2.2089

P/FCF

-2.0885

P/OCF

-2.3654

P/CF

-2.3654

PEG

-0.0610

P/S

0.0000

EV Multiple

-3.0125

P/FV

26.1148

DPS

0.0000

Latest Headlines (EST)

Benzinga May 02, 22:30 STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - ALBT, NDOI, DNB, RSLS GlobeNewswire Inc. May 01, 23:00 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – ALBT, NDOI, DNB, RSLS GlobeNewswire Inc. Mar 23, 22:59 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders GlobeNewswire Inc. Feb 16, 04:17 ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering GlobeNewswire Inc. Jun 04, 00:18 Solaris Files Final Short Form Prospectus in connection with Common Share Bought Deal Offering GlobeNewswire Inc. Jan 11, 06:30 Solaris Announces $130 Million Strategic Investment by Zijin Mining Group GlobeNewswire Inc. Jan 09, 08:30 SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients GlobeNewswire Inc. Jan 03, 20:05 SELLAS Life Sciences Announces Proposed Public Offering GlobeNewswire Inc. Jan 03, 20:05 SELLAS Life Sciences Announces Proposed Public Offering GlobeNewswire Inc. Jan 03, 20:05 SELLAS Life Sciences Announces Proposed Public Offering GlobeNewswire Inc. Jan 03, 20:05 SELLAS Life Sciences Announces Proposed Public Offering GlobeNewswire Inc. Jan 03, 07:30 SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones GlobeNewswire Inc. Dec 27, 08:55 SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma GlobeNewswire Inc. Dec 20, 08:31 ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives GlobeNewswire Inc. Dec 14, 08:30 SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia PennyStocks Dec 13, 17:30 3 Penny Stocks Under $1 To Watch After December Fed Meeting GlobeNewswire Inc. Dec 13, 08:30 SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET Benzinga Dec 12, 17:19 Why ReShape Lifesciences Jumped After-Hours GlobeNewswire Inc. Dec 04, 08:47 SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia GlobeNewswire Inc. Nov 29, 08:45 SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.00 12/09/2010 11/30/-0001 11/30/-0001 12/20/2010
0.00 09/09/2010 09/07/2010 11/30/-0001 09/22/2010